Prof. Rino Rappuoli is known globally for his work on vaccines discovery and immunology. He co-founded the field of cellular microbiology, a discipline combining cell biology and microbiology, and pioneered the genomic approach to vaccine development known as reverse vaccinology, an improvement of vaccinology that employs bioinformatics and reverse pharmacology practices.

Building on the success of our first issue, we are excited to continue our mission of informing, educating and promoting knowledge in vaccinology and vaccination. In our "Coffee with an Expert" section, we are honored...

Israel has agreed to a series of “humanitarian pauses” in Gaza to allow for the vaccination of children against polio, the World Health Organization (WHO) has said. The campaign will aim to vaccinate around 640,000...

Latest impactful scientific publications that stand out for their potential bearing on healthcare. We introduce groundbreaking research findings, innovative treatment modalities, results from phase 1 to 3 vaccine clinical trials, or paradigm-shifting discoveries that redefine our understanding of infectious diseases and therapeutic approaches for all vaccine-preventable diseases.

The COVID-19 pandemic revealed our society's vulnerability to a novel pathogen capable of causing a potentially devastating pandemic. Accordingly, global preparedness is essential. Since November 2022, a new approach by the World Health Organization (WHO)...

Hepatitis A virus (HAV) causes inflammatory liver disease that may progress to fulminant liver failure. HAV is transmitted primarily via the fecal/oral route through ingestion of contaminated food and water, or through direct contact...

The U.S. Food and Drug Administration’s (FDA’s) Center for Biologics Evaluation and Research (CBER) is responsible for regulating vaccine use in the United States. The general stages of vaccine development are: Research and Discovery Proof of Concept ...

One of the most controversial business decisions for the healthcare industry is to establish equitable access to essential medicines and technology with a reasonable return on investment after spending a significant amount on failed vaccines, or any drug, before reaching a successful one. Pharmaceuticals set drug prices with the argument that it finances research and development (R&D) for better treatments or for the development of a vaccine. Even if this calculation is true, maximizing profits for shareholders might be a variable of influence at the expense of access to medicines and, arguably, beyond ethical standards.